Shares Outstanding (Quarterly) Chart

View Shares Outstanding (Quarterly) for AKTX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shares Outstanding (Quarterly) Chart
Start Trial

Historical Shares Outstanding (Quarterly) Data

View and export this data back to 2013. Start Trial.
Date Value
June 30, 2026 1.750M
March 31, 2026 1.145M
December 31, 2025 1.132M
September 30, 2025 0.8154M
June 30, 2025 0.8154M
March 31, 2025 28.88M
December 31, 2024 0.6648M
September 30, 2024 12.14M
June 30, 2024 12.14M
March 31, 2024 7.987M
March 31, 2023 0.1264M
June 30, 2022 2.968M
March 31, 2022 2.968M
December 31, 2021 2.380M
September 30, 2021 2.380M
June 30, 2021 1.982M
March 31, 2021 1.924M
December 31, 2020 1.924M
September 30, 2020 0.0423M
June 30, 2020 0.0423M
March 31, 2020 0.0359M
December 31, 2019 1.123M
Date Value
September 30, 2019 1.050M
June 30, 2019 0.8253M
March 31, 2019 0.7928M
December 31, 2018 0.7903M
September 30, 2018 0.7903M
June 30, 2018 0.7628M
March 31, 2018 0.7628M
December 31, 2017 0.7628M
September 30, 2017 0.5888M
June 30, 2017 0.5888M
March 31, 2017 0.5888M
December 31, 2016 0.5888M
September 30, 2016 0.5888M
June 30, 2016 0.5888M
March 31, 2016 0.5888M
December 31, 2015 0.5888M
September 30, 2015 0.5888M
June 30, 2015 0.0278M
March 31, 2015 0.0278M
December 31, 2013 0.0201M
September 30, 2013 0.0201M

Shares Outstanding Definition

The volume of stock shares issued by the company and in the hands of the public. This number entails how much is being traded in the open market. A decreasing shares outstanding over time may be the result of company buybacks. Companies frequently make stock buybacks and retire those buybacks as treasury stock.

Read full definition.

Shares Outstanding (Quarterly) Range, Past 5 Years

View Shares Outstanding (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shares Outstanding (Quarterly) Benchmarks

View Shares Outstanding (Quarterly) Benchmarks
Start Trial
DBV Technologies SA 59.18M
Cellectis SA 100.70M
argenx SE --
Autolus Therapeutics Plc 266.16M
Evaxion AS 8.340M